Literature DB >> 35510349

Simple and Sensitive RP-HPLC and UV Spectroscopic Methods for the Determination of Remogliflozin Etabonate in Pure and Pharmaceutical Formulations

Nandeesha Itigimatha1, Kailash S Chadchan2, Basappa C Yallur1, Manjunatha D Hadagali3.   

Abstract

Simple, novel and selective reverse phase-high performance liquid chromatography (RP-HPLC) and ultraviolet (UV) spectroscopic methods have been developed and optimized for the determination of remogliflozin etabonate (RMZ) in bulk and dosage forms. In the HPLC method, the principal peak and internal standard peak were eluted separately at different retention times (RT) with the chromatographic conditions such as, mobile phase consisting of 0.02 M ammonium acetate buffer (pH was adjusted to 4.0 by 1.0 M ortho phosphoric acid), acetonitrile and tetrahydrofuran in the ratio 50:45:05, respectively (v/v) and the stationary phase used was C18, 5 μm, 4.6 mm x 250 mm kromasil column. The flow rate was 2.0 mL min-1, sample injection volume was 10 μL, and the wavelength of detection was fixed at 228 nm. In case UV spectroscopic method, the RMZ was diluted with pure ethanol. The RMZ showed a maximum absorbance at 228 nm. Hence throughout analysis 228 nm was used for the determination of RMZ. The RT of RMZ and internal standard, atorvastatin (ATST) were 6.2 min and 7.0 min, respectively. The resolution between the peaks was found to be more than 2.0. The total run time was fixed at 10 min. The linearity range for RP-HPLC method was found to be 10 μg mL-1 to 50 μg mL-1, at a fixed concentration of ATST. The linearity range for the UV spectroscopic method was found to be in the range of 100 to 250 μg mL-1. Regression coefficients (R2) were found above 0.999 for both of the techniques. The limit of detection and quantification for RMZ were found to be 1.0 μg mL-1 and 3.5 μg mL-1 respectively, in RP-HPLC method and 10.0 μg mL-1 and 40 μg mL-1, respectively, in UV spectroscopic method. The developed methods were found to be simple, accurate, reproducible, and precise. The RMZ can be analyzed in dual techniques, i.e., chromatographic and UV spectroscopic methods for its routine analysis.

Entities:  

Keywords:  RP-HPLC; Remogliflozin etabonate; UV spectroscopy; bulk and dosage forms

Year:  2022        PMID: 35510349      PMCID: PMC9083516          DOI: 10.4274/tjps.galenos.2021.55381

Source DB:  PubMed          Journal:  Turk J Pharm Sci        ISSN: 1304-530X


  5 in total

1.  Development and validation of simple spectrophotometric and chemometric methods for simultaneous determination of empagliflozin and metformin: Applied to recently approved pharmaceutical formulation.

Authors:  Bassam M Ayoub
Journal:  Spectrochim Acta A Mol Biomol Spectrosc       Date:  2016-06-06       Impact factor: 4.098

2.  A Novel Analytical Method for the Simultaneous Estimation of Remogliflozin and Metformin Hydrochloride by UPLC/PDA in Bulk and Formulation Application to the Estimation of Product Traces

Authors:  Mohan Rao Tammisetty; Balasekhara Reddy Challa; Srinivasa Babu Puttagunta
Journal:  Turk J Pharm Sci       Date:  2021-06-18

3.  Development and Validation of Green UV Derivative Spectrophotometric Methods for Simultaneous Determination Metformin and Remogliflozin from Formulation: Evaluation of Greenness.

Authors:  Mahesh Attimarad; Anroop B Nair; Nagaraja Sreeharsha; Bandar E Al-Dhubiab; Katharigatta N Venugopala; Pottathil Shinu
Journal:  Int J Environ Res Public Health       Date:  2021-01-08       Impact factor: 3.390

4.  Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.

Authors:  Elizabeth K Hussey; Anita Kapur; Robin O'Connor-Semmes; Wenli Tao; Bryan Rafferty; Joseph W Polli; Charles D James; Robert L Dobbins
Journal:  BMC Pharmacol Toxicol       Date:  2013-04-30       Impact factor: 2.483

5.  Development and validation of the liquid chromatographic method for simultaneous estimation of metformin, pioglitazone, and glimepiride in pharmaceutical dosage forms.

Authors:  Vinay Pandit; Roopa S Pai; Kshama Devi; Gurinder Singh; Satya Narayana; Sarasija Suresh
Journal:  Pharm Methods       Date:  2012-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.